Compare · AVDL vs NVO
AVDL vs NVO
Side-by-side comparison of Avadel Pharmaceuticals plc (AVDL) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVDL and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $196.28B, about 430.0x AVDL ($456.5M).
- Over the past year, AVDL is up 131.8% and NVO is down 45.8% - AVDL leads by 177.5 points.
- NVO has hit the wire 8 times in the past 4 weeks while AVDL has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 15 for AVDL).
- Company
- Avadel Pharmaceuticals plc
- Novo Nordisk A/S
- Price
- $21.67+0.16%
- $43.97+2.76%
- Market cap
- $456.5M
- $196.28B
- 1M return
- +0.77%
- -6.43%
- 1Y return
- +131.76%
- -45.76%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 0
- 8
- Recent ratings
- 15
- 25
Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. The company's lead product candidate is FT218, a formulation of sodium oxybate which is in a Phase 3 clinical trial for the treatment excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AVDL
- SEC Form 15-12G filed by Avadel Pharmaceuticals plc
- Former 10% Owner Weiss Asset Management Lp sold $233,353,092 worth of Ordinary Shares (11,112,052 units at $21.00) (SEC Form 4)
- New insider Weiss Asset Management Lp claimed ownership of 11,112,052 units of Ordinary Shares (SEC Form 3)
- Amendment: SEC Form SCHEDULE 13G/A filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form EFFECT filed by Avadel Pharmaceuticals plc
- SEC Form 4 filed by Chief Operating Officer Rodriguez Susan
- Director Thornton Peter J. returned $2,416,260 worth of Ordinary Shares to the company (115,060 units at $21.00), closing all direct ownership in the company (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care